A1RG34:BVMF
Argenx Se Bdr
R$201.80
0.00%
(0.00) 1D
āļāļŊāˇ 5, 12.25.06 āļāˇâāļģāˇāļ¸āˇāˇ-3 · BRL
search
āˇāˇāļēāļŊāˇ āˇāļāļāˇāļ
| āˇāļāļāˇāļāļē | āļ¸āˇāļŊ | āˇāˇāļąāˇāˇ āļāˇāļģāˇāļ¸ | % āˇāˇāļąāˇ |
|---|
insights_autoA1RG34 āˇāļŗāˇāˇ āļāˇāˇ
āļ¸ āļāļāˇāˇ
āˇāļąāˇāļāļēāļąāˇ āļāļāˇāļ´āˇāļ¯āļąāļē āļāļģāļ¸āˇāļąāˇ...
āˇāˇ.āļ´āˇ āļ´āˇâāļģāˇāļāˇāļ°āļąāļē
āļļāˇ50.16
āļ¯āˇ
āļ´āļģāˇāļ¸āˇāˇ
46.00
āˇāļŦ āļ´āļģāˇāļ¸āˇāļĢāļē
0.00
āˇāļāˇ-52 āļāˇāˇ
R$213.15
āˇāļāˇ-52 āļ´āˇāˇ
R$143.22
āļāˇāˇāˇāļē āļēāˇāļāˇ āļāˇāļ§āˇāˇ
āļ¸āˇ62.89
āˇāˇāˇāļāļēāˇāļąāˇ āļāļĢāļą
āļ¯2
āˇāˇ.āļ´āˇ āļ´āˇâāļģāˇāļāˇāļ°āļąāļē
āļļāˇ50.16
āļ¯āˇ
āļ´āļģāˇāļ¸āˇāˇ
46.00
āˇāļŦ āļ´āļģāˇāļ¸āˇāļĢāļē
0.00
āˇāļāˇ-52 āļāˇāˇ
R$213.15
āˇāļāˇ-52 āļ´āˇāˇ
R$143.22
āļāˇāˇāˇāļē āļēāˇāļāˇ āļāˇāļ§āˇāˇ
āļ¸āˇ62.89
āˇāˇāˇāļāļēāˇāļąāˇ āļāļĢāļą
āļ¯2
āļ´āˇāˇāļāˇ āˇāˇ āļāļŽāˇ
āˇāˇāļļāˇ āļ¸āˇāļŊāˇāˇāˇâāļģ āˇāˇ āļ´āˇâāļģāˇāˇāļāˇāļāˇ āˇāˇāˇāļŊāˇāļāļģāˇāˇāļąāˇāļāˇāļąāˇ
Yahoo Finance
·
āļ´āˇāļē 2āļāļ§ āļ´āˇāļģ
What SPDR S&P 500 ETF (SPY) Sold: Apple Leads on Wednesday
Spectrum News
·
āļ´āˇāļē 21āļāļ§ āļ´āˇāļģ
S&P 500 drops 4.4% in worst day since 2025 as AI chips slide
MarketWatch
·
āļ¸āˇāļąāˇāļāˇāļāˇ 54āļāļ§ āļ´āˇāļģ
The S&P 500âs most reliable dividend stocks are beating the market. Hereâs how to play them.
Trefis
·
āļ´āˇāļē 4āļāļ§ āļ´āˇāļģ
S&P 500 Movers | Winners: APP, TPR, VRSK | Losers: SNDK, LITE, MU
āļ´āˇāļāˇāļāļŠ
Argenx SE is a Belgian-Dutch pharmaceutical company specializing in immunology. Argenx specializes in the development of antibody therapies for the treatment of autoimmune diseases and cancer. Its work primarily focuses on the development of orphan drugs. Wikipedia
Argenx Se Bdr āļāˇāļą
CEO-
āˇāˇāˇāļāļēāˇāļąāˇāļ¯1.86
āļāļģāļ¸āˇāļˇ āļāˇ
āˇ2008 āļļāļāˇ 25
āļ¸āˇāļŊāˇāˇāļŽāˇāļąāļē-
āļ
āļāˇāļēHealth Care
Industry-
āˇāˇāļļāˇ āļ
āļŠāˇāˇāļēargenx.com